Infliximab 5 mg/kg ( DrugBank: Infliximab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	5
97	潰瘍性大腸炎	1

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01181765 (ClinicalTrials.gov)	June 2012	12/8/2010	The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy	The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)	Crohn's Disease	Biological: Infliximab 5 mg/kg body weight infused over 2 hours	Janssen Inc.	NULL	Completed	18 Years	N/A	Both	1	Phase 4	Canada
2	JPRN-UMIN000002604	2009/05/01	01/11/2009	Combined therapy of infliximab with surgery in maintenance of remission in Crohn's disease		Crohn's disease	Patients are randomly divided into two groups, groups treated with or without infliximab by staffs of Keio Clinical Research Center at 2 to 4 weeks after surgery. Patients receive infliximab 5 mg/kg at 0, 2, 6 weeks, followed by every 8 weeks for 2 years. Alternatively, patients continue to receive infliximab with intervals of 8 weeks if they received infliximab within 8 weeks from the time point 0. Patients without infliximab receive maintenance therapy without immunomodulators.	Clinical Research Group of inflammatory bowel disease in Japan	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	100	Phase 4	Japan
3	NCT00752622 (ClinicalTrials.gov)	November 2008	12/9/2008	Treatment With Infliximab in a Medical Setting (Study P05587)	Optimization of Treatment With Infliximab in a Medical Setting	Crohn's Disease	Biological: Infliximab 5 mg/kg;Biological: Infliximab 5 mg/kg every 6 weeks;Biological: Infliximab 7 mg/kg every 8 weeks	Merck Sharp & Dohme Corp.	NULL	Terminated	18 Years	N/A	All	100	Phase 4	Canada
4	NCT00269841 (ClinicalTrials.gov)	May 1996	22/12/2005	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease	A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease	Crohn Disease	Drug: Infliximab 10 mg/kg;Drug: Infliximab 5 mg/kg;Drug: Placebo	Centocor, Inc.	NULL	Completed	18 Years	65 Years	Both	94	Phase 3	NULL
5	NCT00269854 (ClinicalTrials.gov)	June 1995	22/12/2005	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease	A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease	Crohn Disease	Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Infliximab 20 mg/kg;Drug: Placebo	Centocor, Inc.	NULL	Completed	18 Years	65 Years	Both	108	Phase 2/Phase 3	NULL

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00207688 (ClinicalTrials.gov)	August 31, 2004	13/9/2005	A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients	A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis	Ulcerative Colitis	Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Placebo	Janssen Research & Development, LLC	Janssen Biologics BV	Completed	N/A	N/A	All	505		New Zealand;Switzerland;United Kingdom;Argentina;Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Israel;Netherlands;United States;Czech Republic